{"id":6199,"date":"2019-10-21T17:04:25","date_gmt":"2019-10-21T11:34:25","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6199"},"modified":"2024-09-17T16:02:44","modified_gmt":"2024-09-17T10:32:44","slug":"emerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/emerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market","title":{"rendered":"\ufeffEmerging drugs bring a positive shift in Global Osteoporosis Market"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d375cde48f4\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d375cde48f4\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market\/#Osteoporosis_is_not_RARE\" >Osteoporosis is not RARE.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market\/#What_exactly_is_Osteoporosis_and_what_causes_it\" >What exactly is Osteoporosis and what causes it?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market\/#Osteoporosis_Therapy_Market\" >Osteoporosis Therapy Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market\/#Companies_working_to_fuel_the_Osteoporosis_market\" >Companies working to fuel the Osteoporosis\nmarket<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market\/#Osteoporosis_Drugs\" >Osteoporosis Drugs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market\/#Unmet_needs_in_Osteoporosis_treatment_market\" >Unmet needs in Osteoporosis treatment market<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Osteoporosis_is_not_RARE\"><\/span><strong>Osteoporosis is not RARE. <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>As per the International Osteoporosis Foundation (IOF), Osteoporosis affects an estimated 75 million people in Europe, USA and Japan.<\/p>\n\n\n\n<p>Approximately 10 million Americans are living with <a href=\"https:\/\/www.delveinsight.com\/report-store\/osteoporosis-market\">Osteoporosis <\/a>and around 44 Million are struggling due to low bone density. &nbsp;<br>Osteoporosis is known to affect over 3 million people in the UK. Moreover, the female preponderance is observed in excess as compared to males in most cases. <\/p>\n\n\n\n<p>Around 30% of all post-menopausal women tend to develop Osteoporosis in the United States and Europe. The ageing population is another cause leading to a higher Osteoporosis incidence.  <\/p>\n\n\n\n<p>Osteoporosis is a \u2018silent disease\u2019 because only a few people have an idea about their actual bone condition. Others don\u2019t realize until they break a bone. <\/p>\n\n\n\n<p>Worldwide, osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds. Out of which, at least 40% of the women and 15-20% of men will sustain one or more fragile bone. In the UK, Osteoporosis results in around 300,000 fractures every year. About 1 in 2 women and 1 in 5 men over the age of 50 break a bone due to their weak bones. <\/p>\n\n\n\n<p>Osteoporosis is a global burden on the healthcare sector. The cost of care associated with it takes a toll on the patients and their families. According to the National Osteoporosis Foundation, <strong>Osteoporosis is costly<\/strong>. For all the bones that break every year, there is an estimated expenditure of USD 19 Billion. This expense is going to increase to USD 25.3 Billion annually by 2025. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_exactly_is_Osteoporosis_and_what_causes_it\"><\/span><strong>What exactly is Osteoporosis and what causes it?\n<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Osteoporosis is a bone disease\nthat occurs when bones become porous and weak. In some severe cases, the bones\ntend to break even from minor injuries and sneezing. <\/p>\n\n\n\n<p>It occurs when there is and the disparity between new bone formation and old bone resorption. The body fails to form new bones and there is too much reabsorption of the older ones. Moreover, the lower levels of estrogen in women and androgen in men result in hollow and weaker bones.&nbsp; <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Osteoporosis_Therapy_Market\"><\/span><strong>Osteoporosis Therapy Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>The Osteoporosis treatments are\nsegmented on the basis of the different drug classes available to treat it. The\npopular drug classes that are administered include calcitonin, bisphosphonates,\nparathyroid hormone therapy (PTH), RANK ligand inhibitors (denosumab),\nselective estrogen receptor inhibitors (SERMs) and others (estrogen therapy and\ncalcium and vitamin D).<\/p>\n\n\n\n<p>Bisphosphonates are the vital medicines used to treat bone loss and renew bone density. Raloxifene (Evista) manages to reduce the risk of spinal bone fractures. &nbsp;Whereas, Denosumab (Prolia) restores the bone density. Teriparatide (Forteo), on the other hand, helps in increasing bone strength. <\/p>\n\n\n\n<p>Estrogen, or hormone replacement therapy (HRT) is\nalso administered to prevent Osteoporosis. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Companies_working_to_fuel_the_Osteoporosis_market\"><\/span><strong>Companies working to fuel the Osteoporosis\nmarket<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Many players, such as Radius Health, Enteris Pharma, Allergan, Amgen, Astellas Pharma, AstraZeneca, Azelon Pharmaceuticals, Daiichi Sankyo, Eli Lilly, Entera Bio, F. Hoffman-La Roche, Gedeon Richter, Merck &amp; Co, Mereo Biopharma and many others are involved in developing therapies for Osteoporosis. Launch of <a href=\"https:\/\/www.delveinsight.com\/report-store\/osteoporosis-epidemiology-forecast\">Osteoporosis <\/a>emerging therapies like TYMLOS (Radius Health; received FDA approval in August 2017), Romosozumab (Amgen), and Tbria (Enteris Pharma-Tarsa Therapeutics; NDA submitted) will change the Osteoporosis treatment landscape in the upcoming years.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Osteoporosis_Drugs\"><\/span><strong>Osteoporosis Drugs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>At present, Amgen\u2019s Xgeva (denosumab) and Prolia (denosumab) dominates the Osteoporosis therapeutic market. Launched in the year 2010, Xgeva is marketed primarily in the US and Europe. The sales crossed USD 1.5 Billion annually in the year 2016. Prolia and Xgeva constitute the same active ingredient but, however, they are indicated for different indications, and patient population and dosages. In terms of revenue, Prolia made the annual revenue worth USD 1.6 billion for the company.<\/p>\n\n\n\n<p>The US Food and Drug Administration (FDA) Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC) have approved Amgen and UCB\u2019s Romosozumab (<strong>EVENITY<\/strong>) earlier in this year for the treatment of women with <a href=\"https:\/\/www.delveinsight.com\/report-store\/post-menopausal-osteoporosis-market\"><strong>postmenopausal osteoporosis<\/strong> <\/a>at high risk for fracture. <\/p>\n\n\n\n<p>Recently, Amgen and UCB announced a positive recommendation from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Market authorization for EVENITY for the treatment of severe postmenopausal osteoporosis in women at high risk of fracture and with no history of myocardial infarction or stroke.<\/p>\n\n\n\n<p>EVENITY works by hampering the action of sclerostin,\nwhich lowers down the bone density. Romosozumab binds sclerostin, inactivates\nit, and increases the bone formation. These findings stimulated interest in exploring\nthe potential of anti-sclerostin therapy to improve bone formation, restore skeletal\narchitecture and reduce bone damage in patients with osteoporosis.<\/p>\n\n\n\n<p>However, the increased risks of cardiovascular diseases such as stroke, or heart attack even cardiovascular death, might prove to be a barrier in the Osteoporosis therapeutic market.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"mce_7\"><span class=\"ez-toc-section\" id=\"Unmet_needs_in_Osteoporosis_treatment_market\"><\/span><strong>Unmet needs in Osteoporosis treatment market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>The current unmet needs in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/post-menopausal-osteoporosis-pipeline-insight\">Osteoporosis <\/a>treatment are long-term management of the disease, treating severe osteoporosis, identification of the fractures and risk following any recent fracture. There is still scope for developing bone-building treatments with the focus to shift towards a more personalized treatment approach.<br><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Osteoporosis is not RARE. As per the International Osteoporosis Foundation (IOF), Osteoporosis affects an estimated 75 million people in Europe, USA and Japan. Approximately 10 million Americans are living with Osteoporosis and around 44 Million are struggling due to low bone density. &nbsp;Osteoporosis is known to affect over 3 million people in the UK. Moreover, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6201,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[1500,6616,3278,17703,6615],"industry":[17225],"therapeutic_areas":[17241],"class_list":["post-6199","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-facts-and-figures","tag-osteoporosis","tag-osteoporosis-drugs","tag-osteoporosis-market","tag-osteoporosis-pipeline","tag-osteoporosis-therapy-market","industry-pharmaceutical","therapeutic_areas-musculoskeletal"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novel Therapies Fuel Expansion in the Global Osteoporosis Market<\/title>\n<meta name=\"description\" content=\"Presently, Amgen\u2019s Xgeva (denosumab) and Prolia (denosumab) dominates the Osteoporosis therapeutic market. The Osteoporosis treatments are...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novel Therapies Fuel Expansion in the Global Osteoporosis Market\" \/>\n<meta property=\"og:description\" content=\"Presently, Amgen\u2019s Xgeva (denosumab) and Prolia (denosumab) dominates the Osteoporosis therapeutic market. The Osteoporosis treatments are...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/emerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-21T11:34:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T10:32:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09031022\/global_osteoporosis.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novel Therapies Fuel Expansion in the Global Osteoporosis Market","description":"Presently, Amgen\u2019s Xgeva (denosumab) and Prolia (denosumab) dominates the Osteoporosis therapeutic market. The Osteoporosis treatments are...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/emerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market","og_locale":"en_US","og_type":"article","og_title":"Novel Therapies Fuel Expansion in the Global Osteoporosis Market","og_description":"Presently, Amgen\u2019s Xgeva (denosumab) and Prolia (denosumab) dominates the Osteoporosis therapeutic market. The Osteoporosis treatments are...","og_url":"https:\/\/www.delveinsight.com\/blog\/emerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-10-21T11:34:25+00:00","article_modified_time":"2024-09-17T10:32:44+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09031022\/global_osteoporosis.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market","url":"https:\/\/www.delveinsight.com\/blog\/emerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market","name":"Novel Therapies Fuel Expansion in the Global Osteoporosis Market","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09031022\/global_osteoporosis.jpg","datePublished":"2019-10-21T11:34:25+00:00","dateModified":"2024-09-17T10:32:44+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Presently, Amgen\u2019s Xgeva (denosumab) and Prolia (denosumab) dominates the Osteoporosis therapeutic market. The Osteoporosis treatments are...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/emerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09031022\/global_osteoporosis.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09031022\/global_osteoporosis.jpg","width":772,"height":482,"caption":"Osteoporosis Market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09031022\/global_osteoporosis-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Osteoporosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Osteoporosis drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Osteoporosis market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Osteoporosis Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Osteoporosis therapy Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Osteoporosis<\/span>","<span class=\"advgb-post-tax-term\">Osteoporosis drugs<\/span>","<span class=\"advgb-post-tax-term\">Osteoporosis market<\/span>","<span class=\"advgb-post-tax-term\">Osteoporosis Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Osteoporosis therapy Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Oct 21, 2019","modified":"Updated on Sep 17, 2024"},"absolute_dates_time":{"created":"Posted on Oct 21, 2019 5:04 pm","modified":"Updated on Sep 17, 2024 4:02 pm"},"featured_img_caption":"Osteoporosis Market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6199"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6199\/revisions"}],"predecessor-version":[{"id":29548,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6199\/revisions\/29548"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/6201"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6199"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6199"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}